Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Status:
Completed
Trial end date:
2023-02-09
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, open-lable, single-dose, two-cycle, double-cross bioequivalence
study comparing the pharmacokinetic profile of LY01612 (Doxorubicin hydrochloride liposome
injection) and CAELYX® in Chinese subjects with advanced breast cancer